INO Feb 2025 3.000 call
| Previous close | 5.54 |
| Open | 5.54 |
| Bid | 4.10 |
| Ask | 6.30 |
| Strike | 3.00 |
| Expiry date | 2025-02-21 |
| Day's range | 5.54 - 5.54 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
PR NewswireINOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc.
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that INOVIO's President and CEO, Dr. Jacqueline Shea, and Chief Medical Officer, Dr. Michael Sumner will participate in a virtual fireside chat hosted by Sudan Loganathan, Ph.D., Managing Director and equity research analyst at Stephens, Inc.
PR NewswireINOVIO Reports Inducement Grants Under Inducement Plan
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").
- GuruFocus.com
Inovio Pharmaceuticals Inc (INO) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Explore key financial outcomes and strategic updates from Inovio Pharmaceuticals Inc's first quarter of 2024, signaling robust progress and operational efficiency.
